Scholarlink

<p>Ensifentrine (OHTUVAYRE<sup>™</sup>), a first-in-class, dual inhibitor of phosphodiesterase (PDE) enzymes PDE3 and PDE4, is a novel, steroid-free therapeutic option approved in the USA for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. The dual mechanism of ensifentrine provides both bronchodilator and anti-inflammatory effects in the lungs. In two phase 3 clinical trials in adults with moderate to severe COPD, twice-daily nebulized ensifentrine significantly improved lung function at week 12 compared with placebo. Over 24 weeks, ensifentrine improved patient-reported COPD symptoms and health-related quality of life, with statistically significant differences versus placebo in one of the two trials. In a pooled analysis of both trials, ensifentrine significantly reduced the rate of moderate or severe COPD exacerbations over 24 weeks compared with placebo. Ensifentrine was generally well tolerated over up to 48 weeks.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Ensifentrine in chronic obstructive pulmonary disease: a profile of its use

  • 期刊论文

  • 发表日期：

    2025年9月29日

查看全文
  • Amy Zhuang-Yan,
  • Yahiya Y. Syed

摘要

Ensifentrine (OHTUVAYRE™), a first-in-class, dual inhibitor of phosphodiesterase (PDE) enzymes PDE3 and PDE4, is a novel, steroid-free therapeutic option approved in the USA for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. The dual mechanism of ensifentrine provides both bronchodilator and anti-inflammatory effects in the lungs. In two phase 3 clinical trials in adults with moderate to severe COPD, twice-daily nebulized ensifentrine significantly improved lung function at week 12 compared with placebo. Over 24 weeks, ensifentrine improved patient-reported COPD symptoms and health-related quality of life, with statistically significant differences versus placebo in one of the two trials. In a pooled analysis of both trials, ensifentrine significantly reduced the rate of moderate or severe COPD exacerbations over 24 weeks compared with placebo. Ensifentrine was generally well tolerated over up to 48 weeks.